RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing how safe and effective a combination of two new drugs, mezigdomide and elranatamab, is for people with multiple myeloma that has come back or stopped responding to other treatments. The first part of the study will find the best dose, and the second part wil…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo therapy tested for advanced blood cancer
Disease control Recruiting nowThis study is testing if a combination of two drugs, elranatamab and isatuximab, can help control multiple myeloma that has returned or stopped responding to other treatments. It will enroll 30 adults whose cancer has progressed after at least two prior therapies. The goal is to …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New hope for Tough-to-Treat blood cancer: experimental drug enters final testing phase
Disease control Recruiting nowThis study is testing an experimental drug called linvoseltamab for people whose multiple myeloma has returned after prior treatments. It will compare linvoseltamab to a standard combination of three other cancer drugs. The goal is to see which treatment is more effective at cont…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Shielding vulnerable patients: new strategy to block deadly infections during cancer therapy
Prevention Recruiting nowThis study aims to see if a drug called letermovir can prevent serious CMV infections in adults with advanced multiple myeloma. The 40 participants are receiving a new immunotherapy (elranatamab) which can weaken their immune systems and make them prone to infections. Researchers…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Prevention
Last updated Mar 30, 2026 14:28 UTC
-
Looking back: how do new myeloma drugs perform in the real world?
Knowledge-focused Recruiting nowThis study aims to understand how two newer immunotherapy drugs (teclistamab and talquetamab) work for patients with advanced multiple myeloma in real-world medical settings, not in controlled clinical trials. Researchers will look back at the medical records of about 900 patient…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC